{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:44:50Z","timestamp":1790419490406,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS088766"],"award-info":[{"award-number":["R01 NS088766"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R61 NS111079-01"],"award-info":[{"award-number":["R61 NS111079-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM8432-27 \/28"],"award-info":[{"award-number":["GM8432-27 \/28"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ymgme.2021.03.013","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:06:18Z","timestamp":1617235578000},"page":"185-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome"],"prefix":"10.1016","volume":"133","author":[{"given":"Shih-hsin","family":"Kan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Elsharkawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Q.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Prill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linley","family":"Mangini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett E.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia I.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2021.03.013_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgme.2021.03.013_bb0010","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10545-008-0838-5","article-title":"Sanfilippo syndrome: a mini-review","volume":"31","author":"Valstar","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TACG.S57672","article-title":"Sanfilippo syndrome: causes, consequences, and treatments","volume":"8","author":"Fedele","year":"2015","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0020","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1073\/pnas.93.12.6101","article-title":"The molecular basis of Sanfilippo syndrome type B","volume":"93","author":"Zhao","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.ejhg.5200242","article-title":"Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes","volume":"7","author":"Weber","year":"1999","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0030","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/humu.1189","article-title":"Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: diagnostic, clinical, and biological implications","volume":"18","author":"Yogalingam","year":"2001","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0035","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2165\/00003495-200767180-00005","article-title":"Treatment of lysosomal storage disorders - Progress with enzyme replacement therapy","volume":"67","author":"Rohrbach","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ymgme.2021.03.013_bb0040","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0045","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for Mucopolysaccharidoses: past, present, and future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1005526628598","article-title":"Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling","volume":"22","author":"Sivakumur","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0055","first-page":"63","article-title":"Early umbilical cord blood-derived stem cell transplantation does not prevent neurological deterioration in mucopolysaccharidosis type III","volume":"18","author":"Welling","year":"2015","journal-title":"JIMD Rep"},{"key":"10.1016\/j.ymgme.2021.03.013_bb0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/prep.2000.1361","article-title":"Expression and characterization of human recombinant and alpha-N-actylglucosaminidase","volume":"21","author":"Weber","year":"2001","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0065","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1006\/prep.2000.1230","article-title":"Purification and characterization of recombinant human alpha-N-acetylglucosaminidase secreted by Chinese hamster ovary cells","volume":"19","author":"Zhao","year":"2000","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0070","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/BJ20130845","article-title":"Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of \u03b1-N-acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts","volume":"458","author":"Kan","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0075","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1073\/pnas.74.5.2026","article-title":"Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts","volume":"74","author":"Kaplan","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0080","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1042\/bst0180367","article-title":"Lysosomal enzyme targeting","volume":"18","author":"Kornfeld","year":"1990","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0085","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0896-6273(02)01054-1","article-title":"Drug and gene delivery to the brain: the vascular route","volume":"36","author":"Pardridge","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.ymgme.2021.03.013_bb0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.omtm.2017.05.009","article-title":"Clearance of Heparan sulfate and attenuation of CNS pathology by Intracerebroventricular BMN 250 in Sanfilippo type B mice","volume":"6","author":"Aoyagi-Scharber","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ymgme.2021.03.013_bb0095","doi-asserted-by":"crossref","first-page":"14870","DOI":"10.1073\/pnas.1416660111","article-title":"Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB","volume":"111","author":"Kan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207836","article-title":"BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis","volume":"14","author":"Yogalingam","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2021.03.013_bb0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omtm.2019.05.008","article-title":"Differential uptake of NAGLU-IGF2 and unmodified NAGLU in cellular models of Sanfilippo syndrome type B","volume":"14","author":"Prill","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ymgme.2021.03.013_bb0110","doi-asserted-by":"crossref","first-page":"14505","DOI":"10.1073\/pnas.96.25.14505","article-title":"Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase","volume":"96","author":"Li","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/bc.BC_3_18","article-title":"Cerebrospinal fluid circulation: what do we know and how do we know it?","volume":"4","author":"Khasawneh","year":"2018","journal-title":"Brain Circ"},{"key":"10.1016\/j.ymgme.2021.03.013_bb0120","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.ymgme.2018.12.083","article-title":"ICV-administered tralesinidase alfa (BMN 250 NAGLU-IGF2) is well-tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB)","volume":"126","author":"Cleary","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.03.013_bb0125","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.ymgme.2017.12.270","article-title":"ICV-administered BMN 250 (NAGLU-IGF2) is well tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB)","volume":"123","author":"Muschol","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ymgme.2018.12.003","article-title":"Final results of the phase 1\/2, open-label clinical study of intravenous recombinant human N-acetyl-\u03b1-d-glucosaminidase (SBC-103) in children with mucopolysaccharidosis IIIB","volume":"126","author":"Whitley","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ymgme.2013.03.005","article-title":"Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice","volume":"109","author":"Baldo","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0140","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ymgme.2020.05.001","article-title":"Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model","volume":"130","author":"Santi","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1203\/01.PDR.0000129661.40499.12","article-title":"Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice","volume":"56","author":"Gliddon","year":"2004","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0150","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ymgme.2014.05.013","article-title":"Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions?","volume":"114","author":"Tomatsu","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0155","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ymgme.2012.07.002","article-title":"Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model","volume":"107","author":"Rowan","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001380","article-title":"Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I","volume":"2","author":"Dierenfeld","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.omtm.2018.06.005","article-title":"Genetically corrected iPSC-derived neural stem cell grafts deliver enzyme replacement to affect CNS disease in Sanfilippo B mice","volume":"10","author":"Clarke","year":"2018","journal-title":"Mol. Therapy-Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nchembio.766","article-title":"Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses","volume":"8","author":"Lawrence","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ymgme.2021.03.013_bb0175","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ymgme.2013.07.016","article-title":"Glycan-based biomarkers for mucopolysaccharidoses","volume":"111","author":"Lawrence","year":"2014","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221000809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221000809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:48:36Z","timestamp":1778590116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719221000809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1096719221000809"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.03.013","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}